Drug intelligence / Profile preview

AVZO-022

Development stage: Preclinical
Lead developer: Avenzo Therapeutics
Modality: Small Molecules

Overview

AVZO-022 (also known as ARTS-022) is a selective small-molecule inhibitor of Cyclin-Dependent Kinase 4 (CDK4) being developed by Avenzo Therapeutics. It is designed for the treatment of hormone receptor-positive (HR+) breast cancer and other advanced solid tumors. By selectively targeting CDK4 while potentially sparing CDK6, AVZO-022 aims to reduce the hematologic toxicities, such as neutropenia, frequently associated with dual CDK4/6 inhibitors. The candidate is currently in the IND-enabling stage of development.

Targets

CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on AVZO-022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVZO-022.

Explore the full profile